Back to top
more

Cara Therapeutics (CARA)

(Delayed Data from NSDQ)

$0.66 USD

0.66
100,564

0.00 (0.17%)

Updated Apr 22, 2024 11:55 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CARA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Cara Therapeutics, Inc. [CARA]

Reports for Purchase

Showing records 1 - 20 ( 55 total )

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/19/2023

Company Report

Pages: 6

Oral DFK Misses High Bar in AD-Pruritus; Now Look to 2H24 Data in Other Indications; Lower to $2.50, But Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/14/2023

Company Report

Pages: 8

Big Disconnect Between Stock and Oral DFK Potential; Crucial Atopic Derm Data in December; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

10/19/2023

Company Report

Pages: 7

Shifting Gears: Now an Oral DFK Story; Street Sleeping on Important Atopic Derm Data by December; New $7 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/16/2023

Company Report

Pages: 6

IV Korsuva Slower Acceleration Than We’d Modeled; See Similar Peak Opportunity But Moderated Ramp; PT Lower to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/07/2023

Company Report

Pages: 7

Big 4Q Inventory Drag Spooks Street; We Lower, But Think Reaction to Temporarily Depressed Ramp is Overdone; PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/14/2023

Company Report

Pages: 6

Moderating Initial IV Korsuva Patient Ramp to Account for Inventory Dynamics; Strongly Reiterate Buy But Lower PT to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/08/2022

Company Report

Pages: 6

3Q22: Korsuva Injection Volume Ramp Should Dispel Launch Doubts and Inject Life into the Stock; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/09/2022

Company Report

Pages: 6

Korsuva Profitability Even Higher Than We Thought; Makes Up for Later to Ramp Big Dialysis Center Orders; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/10/2022

Company Report

Pages: 6

1Q22: IV Korsuva Partner Launch Underway and Underappreciated; Major Valuation Disconnect, In Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/14/2022

Company Report

Pages: 8

IV Korsuva Launch Weeks Away; Oral Korsuva Phase 3s Take Shape; Moderating Target on Long-Term Pricing

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/09/2021

Company Report

Pages: 6

3Q21: Stock Undervalues Imminent IV Korsuva Launch, In Our View; Oral Korsuva Phase 3 Plans Taking Shape; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CARA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/24/2021

Company Report

Pages: 7

IV Korsuva Approved; 1Q22 Launch; Raise PT to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/10/2021

Company Report

Pages: 6

2Q21: IV Korsuva PDUFA 2 Weeks Away; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/11/2021

Company Report

Pages: 7

1Q21: Undervalued Ahead of IV Korsuva August PDUFA; Potential Less-Risky Pathway in Pre-dialysis CKD-aP

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

04/30/2021

Company Report

Pages: 11

Nothing Changes in Our Valuation; Atopic Dermatitis Wasn''t In Our Model; Reiterate $33 Target Ahead of IV Korsuva PDUFA

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/09/2021

Company Report

Pages: 7

IV Korsuva Gets Priority Review; Imminent Oral Korsuva AD Data Entirely Potential Upside to Our Valuation

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

12/29/2020

Company Report

Pages: 6

IV Korsuva NDA Filed; Project IV Approval Along with Oral Korsuva AD and CLD-aP data by mid-2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/11/2020

Company Report

Pages: 7

3Q20: IV Korsuva Filing This Quarter; 2021 a Transformative Year With IV Launch and the Oral’s Potential Emerging; Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party